Four vaccines have entered clinical phase 3 in China, and 60000 people have been vaccinated without serious adverse reactions

category:Hot
 Four vaccines have entered clinical phase 3 in China, and 60000 people have been vaccinated without serious adverse reactions


On October 15 local time, the lancet, an international authoritative academic journal, published on its official website the latest results of a clinical trial of Chinas new crown vaccine.

It was pointed out that the results of phase I and phase II clinical trials showed that the new inactivated coronal vaccine named bbibp CorV had good immune and safety performance. It is not only effective in healthy people aged 18 to 59, but also safe and effective in the elderly over 60 years old.

Reuters and other foreign media also noted the latest test results of the Chinese new crown vaccine, and introduced that in addition to this vaccine, China has made great achievements in the research and development of the new crown vaccine, which will bring positive impact on the global health cause.

Previously, the Wuhan Institute of biological products published the worlds first clinical trial data of new crown inactivated vaccine published in the Journal of American Medical Association.

The novel coronavirus said that the novel coronavirus pneumonia epidemic is still over, and the test of candidate vaccines is urgently needed. The purpose of the study is to assess the safety and immunogenicity of the BBIBP-CorV new crown inactivated vaccine in humans.

According to the introduction, bbibp CorV new crown inactivated vaccine was jointly developed by Henan Provincial Center for Disease Control and prevention, China biological Beijing Institute of biological products and China Center for Disease Control and prevention.

Phase I and phase II clinical trials have good safety and immunogenicity, and are safe and effective for the elderly

In the phase I study, 192 healthy adults were divided into 18-59 years old group and over 60 years old group with 96 people in each group to evaluate low, medium and high-dose vaccines. At the same time, each group was randomly assigned to receive vaccine or placebo according to the proportion of 3:1.

The results of this trial showed that bbibp CorV new crown inactivated vaccine was safe and well tolerated in both age groups. After 42 days of vaccination, all the vaccinators had high level of McAb, including those over 60 years old with weak immune function, which provided valuable data for the elderly population.

The results of this experiment showed that high neutralizing antibody titer could be obtained by inoculating twice with medium dose each time, and the interval was 21 or 28 days. The control group with all two injections was better than the single vaccination.

In the phase I study, 192 people were randomly assigned to receive different doses of vaccine or placebo. Among the 144 vaccinators, 42 (29%) had adverse reactions in the first 7 days after vaccination, mainly manifested in pain at the vaccination site, followed by fever, but all of them were mild or moderate. No serious adverse reactions were observed within 28 days of vaccination.

In the phase II study, 448 people were randomly assigned to receive different doses of vaccine or placebo. Among the 336 vaccinators, 76 (23%) had adverse reactions in the first seven days after vaccination, mainly manifested in fever; another placebo subject reported grade 3 fever, but it was self limiting and recovered, and these adverse reactions were mild or moderate.

It can be concluded that bbibp CorV new crown inactivated vaccine is safe and well tolerated in both age groups.

Chinas new crown vaccine research and development progress is the worlds leading, will make a great contribution to the global anti epidemic

Chinas bbibp CorV new crown inactivated vaccine test and the results published in the lancet also attracted the attention of Reuters and other foreign media.

In its report agency, Reuters reported that antibodies could be produced in every group of vaccinators, including the elderly, in the bbibp CorV new crown inactivated vaccine trial. In addition to this vaccine, China Biotechnology Group Corporation (China Biology), a subsidiary of China Pharmaceutical Group Co., Ltd., has another candidate vaccine, which is currently undergoing phase III trials overseas.

Reuters pointed out that a senior official of China biology revealed last month that the two candidate vaccines may be conditionally approved for public use this year. According to a research paper published in August this year, another candidate vaccine of China biology can also produce antibodies in phase I and phase II clinical trials without causing serious side effects.

According to China biology, the bbibp CorV new crown inactivated vaccine developed by Beijing Institute of biological products was approved by the State Food and Drug Administration on April 27, and phase I and phase II clinical trials were started simultaneously.

At present, the Beijing Institute of biological products and Wuhan Institute of biological products affiliated to the Chinese Institute of biological products are promoting phase III clinical trials in UAE, Bahrain, Egypt, Morocco, Peru, Argentina and other countries in an orderly manner. The sample population now covers 125 countries, and the progress in all aspects is leading the world.

(function(){( window.slotbydup=window .slotbydup||[]).push({id:u5811557,container:ssp_ 5811557, async:true }Ayelet Berman, a senior researcher at the center for international law at the National University of Singapore, said Chinas participation may bring huge financial support to the program, and Chinas potential to provide vaccines and production capacity for the program will have a positive impact on global vaccine access. Chinas participation in novel coronavirus pneumonia vaccine implementation plan is also a great achievement, Bloomberg said. Because even the possibility of providing vaccines to a small proportion of Chinas 1.4 billion population will increase the critical production of vaccines, thus enhancing the alliances negotiating power. In addition, it wrote in its report that Chinas accession fills the gap in global health leadership in this field after trump rejected the plan and Chinas move has formed a positive contrast with the United States. Source: Beijing daily client editor: Yu changzong_ NBJ11145

Ayelet Berman, a senior researcher at the center for international law at the National University of Singapore, commented that Chinas participation may bring huge financial support to the program, and that Chinas potential to provide vaccines and production capacity for the program will have a positive impact on global vaccine acquisition.

In addition, it wrote in its report that Chinas accession fills the gap in global health leadership in this field after trump rejected the plan and Chinas move has formed a positive contrast with the United States.